Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brentuximab Vedotin in Front-line HL and PTCL
NCT01716806Phase 2Completed
- Sponsor
- Seagen Inc.
- Start
- Oct 2012
- Primary completion
- Apr 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of brentuximab vedotin in Hodgkin lymphoma (HL) and peripheral T-cell lymphoma (PTCL) (6 arms), sponsored by Seagen Inc. Primary endpoint: Objective Response Rate up to 81 months. Started Oct 2012; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT01716806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01716806.